A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy

Trial Profile

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms CERTIFI
  • Most Recent Events

    • 19 Oct 2016 Results of pooled safety analysis from 12 Ustekinumab Crohn's Disease and Psoriatic Diseases trials (n=3636), presented at the 24th United European Gastroenterology Week
    • 02 Nov 2011 Results presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.
    • 26 Oct 2011 Results presented at the 19th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top